908 Devices (NASDAQ:MASS) Given “Overweight” Rating at Stephens

Stephens reiterated their overweight rating on shares of 908 Devices (NASDAQ:MASS) in a research report sent to investors on Wednesday morning,Benzinga reports. Stephens currently has a $6.00 target price on the stock.

A number of other brokerages have also weighed in on MASS. Leerink Partners reaffirmed a “market perform” rating and issued a $4.00 price target (down from $12.00) on shares of 908 Devices in a research note on Wednesday, November 13th. Stifel Nicolaus lowered their price target on 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Finally, Leerink Partnrs cut 908 Devices from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 13th.

908 Devices Stock Performance

NASDAQ:MASS opened at $2.91 on Wednesday. The stock has a market capitalization of $101.33 million, a PE ratio of -1.64 and a beta of 0.96. 908 Devices has a fifty-two week low of $1.81 and a fifty-two week high of $8.50. The company has a fifty day moving average of $2.41 and a two-hundred day moving average of $3.53.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its position in shares of 908 Devices by 6.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 69,550 shares of the company’s stock valued at $358,000 after acquiring an additional 4,212 shares during the last quarter. American Century Companies Inc. raised its stake in 908 Devices by 18.6% during the second quarter. American Century Companies Inc. now owns 33,718 shares of the company’s stock worth $174,000 after purchasing an additional 5,295 shares during the period. Dimensional Fund Advisors LP boosted its holdings in 908 Devices by 88.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 245,176 shares of the company’s stock valued at $1,263,000 after purchasing an additional 114,987 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of 908 Devices by 79.4% in the 2nd quarter. Renaissance Technologies LLC now owns 195,500 shares of the company’s stock valued at $1,007,000 after buying an additional 86,500 shares during the period. Finally, Marshall Wace LLP acquired a new stake in shares of 908 Devices during the 2nd quarter worth approximately $229,000. 88.06% of the stock is owned by hedge funds and other institutional investors.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.